Organogenesis Holdings Inc.

Contributing Author

Recent Articles by Organogenesis Holdings Inc.

Oct-12	Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPlyAM for Hard-to-Heal Diabetic Foot Ulcers ORGO GlobeNewswire
Oct-12	Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026 ORGO GlobeNewswire
Aug-06	Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results ORGO ORGO -22.82% GlobeNewswire
Jul-27	Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity in the Most Challenging and Complex Venous Leg Ulcers ORGO +6.69% GlobeNewswire
Jul-09	Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026 ORGO GlobeNewswire
Jul-06	Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu for the Management of Symptomatic Knee Osteoarthritis ORGO +5.08% GlobeNewswire
May-07	Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results ORGO ORGO -6.32% GlobeNewswire
Apr-28	Organogenesis Completes Rolling Submission of Biologics License Application for ReNu ORGO GlobeNewswire
Apr-06	Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPlyAM ORGO GlobeNewswire
Apr-06	Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu for Knee Osteoarthritis Pain ORGO GlobeNewswire
Apr-06	Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026 ORGO GlobeNewswire
Feb-26	Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue ORGO -9.98% ORGO -13.24% GlobeNewswire
Feb-19	Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026 ORGO GlobeNewswire
Dec-23	Organogenesis Announces Initiation of Biologics License Application for ReNu ORGO GlobeNewswire
Dec-15	Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu for Knee Osteoarthritis Pain ORGO ORGO +7.04% GlobeNewswire
Nov-06	Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance ORGO ORGO +44.73% GlobeNewswire
Nov-03	Organogenesis Applauds CMS's Significant Step In Payment Reform ORGO -5.88% GlobeNewswire
Oct-31	Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ORGO GlobeNewswire
Oct-01	Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025 ORGO GlobeNewswire
Sep-25	Organogenesis Provides Update on Second Phase 3 ReNu Study ORGO ORGO -12.39% GlobeNewswire
Aug-27	Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September ORGO ORGO +5.79% GlobeNewswire
Aug-07	Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results ORGO GlobeNewswire
Jul-22	Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2025 Financial Results on August 7, 2025 ORGO +5.70% GlobeNewswire
Jul-15	Organogenesis Applauds CMS Proposal to Reform Skin Substitute Payment Policy; Urges Refinements to Ensure Patient Access to Appropriate Products and Continued Innovation ORGO -10.24% GlobeNewswire
May-08	Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results ORGO ORGO -42.70% GlobeNewswire

Organogenesis Holdings Inc.

Recent Articles by Organogenesis Holdings Inc.

Upgrade your Finviz experience